Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Pediatric Drugs
Erschienen in: Pediatric Drugs 9/2001

01.09.2001 | Therapy In Practice

Pharmacological Therapy for Patients with Kawasaki Disease

verfasst von: Dr Richard V. Williams, LuAnn L. Minich, Lloyd Y. Tani

Erschienen in: Pediatric Drugs | Ausgabe 9/2001

Einloggen, um Zugang zu erhalten

Abstract

Kawasaki disease is a systemic vasculitis of unknown aetiology that has been reported worldwide since its initial description in Japanese children. The most significant sequelae of acute Kawasaki disease are related to the inflammation of small to medium sized arteries and, in particular, the development of coronary artery aneurysms. Because the aetiology is unknown, pharmacological therapy is nonspecific and directed towards modulation of the inflammatory response and inhibition of platelet activation with the aim of preventing coronary artery aneurysms.
In the US, the recommended treatment for Kawasaki disease in the acute phase is a single, high dose of intravenous gammaglobulin (2 g/kg) and high dose aspirin (80 to 100 mg/kg/day). Use of this regimen has resulted in a significant decrease in the incidence of coronary artery abnormalities. Although the American Heart Association currently recommends high dose aspirin, moderate doses are used in Japan and the optimal dose of aspirin is not known.
There has been renewed interest in the use of corticosteroids in the treatment of acute Kawasaki disease; however, their precise role remains unclear. Newer antiplatelet agents have also shown some promise in the treatment of patients with coronary artery aneurysms. Long term pharmacological therapy consists primarily of anticoagulation in patients with persistent coronary artery abnormalities.
In this review, current recommendations for pharmacological therapy in Kawasaki disease are reviewed and some of the controversies in management of this disease, including management of patients who do not respond to initial therapy and the role of corticosteroids in the acute setting, are outlined.
Literatur
1.
Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54: 271–6PubMed
2.
Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 1991; 119: 279–82PubMedCrossRef
3.
Bell DM, Morens DM, Holman RC, et al. Kawasaki syndrome in the United States. Am J Dis Child 1983; 137: 211–4PubMed
4.
Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993; 87: 1776–80PubMedCrossRef
5.
Stockneim JA, Innocentini N, Shulman ST. Kawasaki disease in older children and adolescents. J Pediatr 2000; 137: 250–2CrossRef
6.
Burns JC, Wiggins JW, Toews WH, et al. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr 1986; 109: 759–63PubMedCrossRef
7.
Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr 1995; 126: 524–9PubMedCrossRef
8.
Rowley AH, Gonzalez-Crussi F, Gidding SS, et al. Incomplete Kawasaki disease with coronary artery involvement. J Pediatr 1987; 110:409–13PubMedCrossRef
9.
Levy M, Koren G. Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. Pediatr Infect Dis J 1990; 9: 122–6PubMedCrossRef
10.
Witt MT, Minich LL, Bohnsack JF, et al. Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria. Pediatrics 1999; 104: E1CrossRef
11.
Choi Y, Lafferty JA, Clements JR, et al. Selective expansion of T cells expressing Vβ2 in toxic shock syndrome. J Exp Med 1990; 172: 981–4PubMedCrossRef
12.
Abe J, Kotzin BL, Meissner C, et al. Characterization of T cell repertoire changes in acute Kawasaki disease. J Exp Med 1993; 177:791–6PubMedCrossRef
13.
Hall M, Hoyt L, Ferrieri P, et al. Kawasaki syndrome-like illness associated with infection caused by enterotoxin B-secreting staphylococcus aureus. Clin Infect Dis 1999; 29: 586–9PubMedCrossRef
14.
Leung DY, Sullivan KE, Brown-Whitehorn TF, et al. Association of toxic shock syndrome toxin-secreting and exfoliative toxin-secreting Staphylococcus aureus with Kawasaki syndrome complicated by coronary artery disease. Pediatr Res 1997; 42: 268–72PubMedCrossRef
15.
Curtis N, Zheng R, Lamb JR, et al. Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child 1995; 72: 308–11PubMedCrossRef
16.
Leung DY, Meissner C, Fulton D, et al. The potential role of bacterial superantigens in the pathogenesis of Kawasaki syndrome. J Clin Immunol 1995; 15Suppl. 6: 11–17SCrossRef
17.
Leung DY, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting staphylococcus aureus in Kawasaki syndrome. Lancet 1993; 342: 1385–8PubMedCrossRef
18.
Morita A, Imada Y, Igarashi H, et al. Serologic evidence that strep-tococcal superantigens are not involved in the pathogenesis of Kawasaki disease. Microbiol Immunol 1997; 41: 895–900PubMed
19.
Terai M, Miwa K, Williams T, et al. The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis 1995; 172: 558–61PubMedCrossRef
20.
Rowley AH, Wolinsky SM, Relman DA, et al. Search for highly conserved viral and bacterial nucleic acid sequences corresponding to an etiologic agent of Kawasaki disease. Pediatr Res 1994; 36: 567–71PubMedCrossRef
21.
Burns JC, Geha RS, Schneeberger EE, et al. Polymerase activity in lymphocyte culture supernants from patients with Kawasaki disease. Nature 1986; 323: 814–6PubMedCrossRef
22.
Lin CY, Chen IC, Cheng TI, et al. Virus-like particles with reverse transcriptase activity associated with Kawasaki disease. J Med Virol 1992; 38: 175–82PubMedCrossRef
23.
Kusakawa S, Tatara K. Efficacies and risks of aspirin in the treatment of Kawasaki disease. Prog Clin Biol Res 1987; 250: 401–13PubMed
24.
Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979; 63: 175–9PubMed
25.
Koren G, Rose V, Lavi S, et al. Probable efficacy of high-dose salicylates in reducing coronary artery involvement in Kawasaki disease. JAMA 1985; 254: 767–9PubMedCrossRef
26.
Burns JC, Glode MP, Clarke SH, et al. Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms. J Pediatr 1984; 105: 206–11PubMedCrossRef
27.
Yokoyama, T, Kato H, et al. Aspirin treatment and platelet function in Kawasaki disease. Kurume Med J 1980; 27: 57–61PubMedCrossRef
28.
Kelton JG, Hirsh J, Carter CJ, et al. Thrombogenic effect of high-dose aspirin in rabbits. J Clin Invest 1978; 62: 892–5PubMedCrossRef
29.
Ratnatunga CP, Edmondson SF, Rees GM, et al. High-dose aspirin inhibits shear-induced platelet reaction involving throm-bin generation. Circulation 1992; 85: 1077–82PubMedCrossRef
30.
Ichida F, Fatica NS, Engle MA, et al. Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk factors and role of aspirin. Pediatrics 1987; 80: 828–35PubMed
31.
Akagi T, Kato H, Inoue O, et al. A study on the optimal dose of aspirin therapy in Kawasaki disease. Kurume Med J 1989; 37: 203–8CrossRef
32.
Melish ME, Takahashi M, Shulman ST, et al. Comparison of low dose aspirin vs high dose aspirin as an adjunct to intravenous gamma globulin in the treatment of Kawasaki syndrome [abstract]. Pediatr Res 1992; 31: 170A
33.
Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96: 1057–61PubMed
34.
Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997; 131: 888–93PubMedCrossRef
35.
Koren G, MacLeod SM. Difficulty in achieving therapeutic serum concentrations of salicylate in Kawasaki disease. J Pediatr 1984; 105: 991–5PubMedCrossRef
36.
Koren G, Schaffer F, Silverman E, et al. Determinants of low serum concentrations of salicylates in patients with Kawasaki disease. J Pediatr 1988; 112: 663–7PubMedCrossRef
37.
Koren G, Silverman E, Sundel R, et al. Decreased protein binding of salicylates in Kawasaki disease. J Pediatr 1991; 118: 456–9PubMedCrossRef
38.
Matsubara T, Mason W, Kashani IA, et al. Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr 1996; 128: 701–3PubMedCrossRef
39.
Furusho K, Sato K, Soeda T, et al. High-dose intravenous gamma globulin for Kawasaki disease [letter]. Lancet 1983; II: 1359CrossRef
40.
Furusho K, Nakano H, Shinomiya K, et al. High-dose intravenous gamma-globulin for Kawasaki disease. Lancet 1984; II: 1055–8CrossRef
41.
Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341–57PubMedCrossRef
42.
Okuni M, Harada K, Yamaguchi H, et al. Intravenous gamma globulin therapy in Kawasaki disease: trial of low dose gamma globulin. Prog Clin Biol Res 1987; 250: 433–9PubMed
43.
Nagashima M, Matsushima M, Matsuoka H, et al. High-dose gamma globulin therapy for Kawasaki disease. J Pediatr 1987; 110: 710–2PubMedCrossRef
44.
Rowley AH, Duffy CE, Shulman ST. Prevention of giant coronary artery aneurysms in Kawasaki disease by intravenous gamma globulin therapy. J Pediatr 1988; 113: 290–4PubMedCrossRef
45.
Engle MA, Fatica NS, Bussel JB, et al. Clinical trial of single-dose intravenous gamma globulin in acute Kawasaki disease. Am J Dis Child 1989; 143: 1300–4PubMed
46.
Barron KS, Murphy DJ, Silverman ED, et al. Treatment of Kawasaki syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. J Pediatr 1990; 117: 638–44PubMedCrossRef
47.
Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633–9PubMedCrossRef
48.
Marasini M, Pongiglione G, Gazzolo D, et al. Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities. Am J Cardiol 1991; 68: 796–7PubMedCrossRef
49.
Shulman ST. IVGG therapy in Kawasaki disease: mechanisms of action. Clin Immunol Immunopathol 1989; 53 (2 Pt 2): S141–6PubMedCrossRef
50.
Leung DY, Burns JC, Newburger JW, et al. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gamma globulin. J Clin Invest 1987; 79: 468–72PubMedCrossRef
51.
Terai M, Jibiki T, Harada A, et al. Dramatic decrease of circulating levels of monocyte chemoattractant protein-1 in Kawasaki disease after gamma globulin treatment. J Leukoc Biol 1999; 65: 566–72PubMed
52.
Takata Y, Seki S, Dobashi H, et al. Inhibition of IL-12 synthesis of peripheral blood mononuclear cells stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease. Clin Exp Immunol 1998; 114: 311–9PubMedCrossRef
53.
Schiller B, Elinder G. Inflammatory parameters and soluble cell adhesion molecules in Swedish children with Kawasaki disease: relationship to cardiac lesions and intravenous immunoglobulin treatment. Acta Pediatr 1999; 88: 844–8CrossRef
54.
Kelly RA, Smith TW. Cytokines and cardiac contractile function. Circulation 1997; 95: 778–81PubMedCrossRef
55.
Moran AM, Newburger JW, Sanders SP, et al. Abnormal myo-cardial mechanics in Kawasaki disease: rapid response to gamma globulin. Am Heart J 2000; 139: 217–23PubMed
56.
Sundel RP, Burns JC, Baker A, et al. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993; 123: 657–9PubMedCrossRef
57.
Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998; 17: 1144–8PubMedCrossRef
58.
Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gamma globulin treatment failure in Kawasaki disease. Pediatrics 2000; 105(6): E78PubMedCrossRef
59.
Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000; 137: 172–6PubMedCrossRef
60.
Yanagawa H, Nakamura Y, Sakata K, et al. Use of intravenous gamma globulin for Kawasaki disease: effects on cardiac sequelae. Pediatr Cardiol 1997; 18: 19–23PubMedCrossRef
61.
Boyce TG, Spearman P. Acute aseptic meningitis secondary to intravenous immunoglobulin in a patient with Kawasaki syndrome. Pediatr Infect Dis J 1998; 17: 1054–5PubMedCrossRef
62.
Comenzo RL, Malachowski ME, Meissner HC, et al. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 1992; 120: 926–8PubMedCrossRef
63.
Fasano MB. Risks and benefits of intravenous immunoglobulin treatment in children. Curr Opinion Pediatr 1995; 7: 688–94PubMed
64.
Klassen TP, Rowe PC, Gafni A. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome. J Pediatr 1993; 122: 538–42PubMedCrossRef
65.
Kijima Y, Kamiya T, Suzuki A, et al. A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease. Jpn Circ J 1982; 46: 1239–42PubMedCrossRef
66.
Nonaka Z, Maekawa K, Okabe T, et al. Randomized controlled study of intravenous prednisolone and gamma globulin treatment in 100 cases with Kawasaki disease. In Kato H, editor. Kawasaki disease: proceedings of the 5th International Kawasaki Disease Symposium. Amsterdam: ElsevierScience BV, 1995: 328–331
67.
Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996; 128: 146–9PubMedCrossRef
68.
Dahlem PG, von Rosenstiel IA, Lam J, et al. Pulse methylpred-nisolone therapy for impending cardiac tamponade in immu-noglobulin-resistant Kawasaki disease. Intensive Care Med 1999; 25: 1137–9PubMedCrossRef
69.
Shinohara M, Sone K, Tomomasa T, et al. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999; 135: 465–9PubMedCrossRef
70.
Bierman FZ, Gersony WM. Kawasaki disease: clinical perspective. J Pediatr 1987; 111: 789–93PubMedCrossRef
71.
Newburger JW. Treatment of Kawasaki disease: corticosteroids revisited. J Pediatr 1999; 135: 411–3PubMedCrossRef
72.
Shulman ST, Rowley AH. Treatment of Kawasaki disease with corticosteroid [letter]. J Pediatr 1996; 129: 483PubMed
73.
Kato H, Ichinose E, Inoue O, et al. Intracoronary thrombolytic therapy in Kawasaki disease: treatment and prevention of acute myocardial infarction. Prog Clin Biol Res 1987; 250: 445–54PubMed
74.
Kato H, Inoue O, Ichinose E, et al. Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction. Acta Paediatr Jpn 1991; 33: 27–35PubMedCrossRef
75.
Suzuki A, Tetsuro K, Ono Y, et al. Thrombolysis in the treatment of patients with Kawasaki disease. Cardiol Young 1993; 3: 207–15CrossRef
76.
Katayama F, Hiraishi S, Takeda N, et al. Intracoronary urokinase and post-thrombolytic regimen in an infant with Kawasaki disease and acute myocardial infarction. Heart 1997; 78: 621–2PubMed
77.
Burtt DM, Pollack P, Bianco JA. Intravenous streptokinase in an infant with Kawasaki disease complicated by acute myocardial infarction. Pediatr Cardiol 1986; 6: 307–11PubMed
78.
Tsubata S, Ichida F, Hamamichi Y, et al. Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease. Pediatr Cardiol 1995; 16: 186–9PubMed
79.
Horigome H, Sekijima T, Miyamoto T. Successful thrombolysis with intracoronary administration of tissue plasminogen activator in an infant with Kawasaki disease. Heart 1997; 78: 517–8PubMed
80.
O’Brien M, Parness IA, Neufeld EJ, et al. Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. Pediatrics 2000; 105(5): E64PubMedCrossRef
81.
Gryglewski RJ, Korbut R, Swies J, et al. Thrombolytic action of ticlopidine: possible mechanisms. Eur J Pharmacol 1996; 308: 61–7PubMedCrossRef
82.
CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39CrossRef
83.
Etheridge SP, Tani LY, Minich LL, et al. Platelet glycoprotein IIa/IIIb receptor blockade therapy for large coronary aneu-rysms and thrombi in Kawasaki disease. Cathet Cardiovasc Diagn 1998; 45: 264–8PubMedCrossRef
84.
Akagi T, Rose V, Benson LN, et al. Outcome of coronary artery aneurysms after Kawasaki disease. J Pediatr 1992; 121: 689–4PubMedCrossRef
85.
Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analysis in 195 cases. J Pediatr 1986; 108: 923–7PubMedCrossRef
86.
Nakanishi T, Takao A, Nakazawa M, et al. Mucocutaneous lymph node syndrome: clinical, hemodynamic and angiographic features of coronary obstructive disease. Am J Cardiol 1985; 55: 662–8PubMedCrossRef
87.
Dajani AS, Taubert KA, Takahashi M, et al. Guidelines for long-term management of patients with Kawasaki disease. Circulation 1994; 89: 916–22PubMedCrossRef
88.
Turpie AGG, Gent M, Laupacis A, et al. Acomparison of aspirin with placebo in patients treated with warfarin after heart valve replacement. N Engl J Med 1993; 329: 524–9PubMedCrossRef
89.
Takahashi M. Management of giant coronary artery aneurysms due to Kawasaki syndrome. ACC Curr J Review 1996; 5(4): 76
90.
Gersony WM. Kawasaki disease: clinical overview. Cardiol Young 1991; 1: 192–5CrossRef
91.
Kobayashi T, Sone K. Effect of dipyridamole on the blood flow in coronary aneurysms resulting from Kawasaki disease. Pediatr Cardiol 1994; 15: 263–7PubMedCrossRef
92.
Newburger JW, Buns JC, Beiser AS, et al. Altered lipid profile after Kawasaki syndrome. Circulation 1991; 84: 625–31PubMedCrossRef
93.
Suzuki A, Miyagawa-Tomita S, Komatsu K, et al. Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease. Circulation 2000; 101: 2935–41PubMedCrossRef
94.
Sugimura T, Kato H, Inoue O, et al. Intravascular ultrasound of coronary arteries in children: assessment of the wall morphology and the lumen after Kawasaki disease. Circulation 1994; 89: 258–65PubMedCrossRef
95.
Suzuki M, Yamagishi M, Kimura K, et al. Functional behavior and morphology of the coronary artery wall in patients with Kawasaki disease assessed by intravascular ultrasound. J Am Coll Cardiol 1996; 27: 291–6PubMedCrossRef
96.
Yamakawa R, Ishii M, Sugimura T, et al. Coronary endothelial dysfunction after Kawasaki disease: evaluation by intracoronary injection of acetylcholine. J Am Coll Cardiol 1998; 31: 1074–80PubMedCrossRef
97.
Sugimura T, Kato H, Inoue O, et al. Vasodilatory response of the coronary arteries after Kawasaki disease: evaluation by intracoronary injection of isosorbide dinitrate. J Pediatr 1992; 121: 684–8PubMedCrossRef
98.
Hamaoka K, Onouchi Z, Kamiya Y, et al. Evaluation of coronary flow velocity dynamics and flow reserve in patients with Kawasaki disease by means of a Doppler guide wire. J Am Coll Cardiol 1998; 31: 833–40PubMedCrossRef
99.
Muzik O, Paridon SM, Singh TP, et al. Quantification of myocardial blood flow and flow reserve in children with a history of Kawasaki disease and normal coronary arteries using positron emission tomography. J Am Coll Cardiol 1996; 28: 757–62PubMedCrossRef
Metadaten
Titel
Pharmacological Therapy for Patients with Kawasaki Disease
verfasst von
Dr Richard V. Williams
LuAnn L. Minich
Lloyd Y. Tani
Publikationsdatum
01.09.2001
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 9/2001
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/00128072-200103090-00003

Weitere Artikel der Ausgabe 9/2001

Pediatric Drugs 9/2001 Zur Ausgabe

Review Article

The Role of Non-Nucleoside Reverse Transcriptase Inhibitors in Children with HIV-1 Infection

Review Article

Psoriasis in Children

Current Opinion

Management of the Extremely Preterm Infant

Current Opinion

The Role of Antibacterial Therapy of Acute Otitis Media in Promoting Drug Resistance

Review Article

Conversion from Cyclosporin to Tacrolimus in Paediatric Liver Transplant Recipients

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise